Last reviewed · How we verify
CagriSema
CagriSema is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.
CagriSema is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management (in development).
At a glance
| Generic name | CagriSema |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Dual GLP-1/glucagon receptor agonist |
| Target | GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | Phase 3 |
Mechanism of action
By simultaneously activating GLP-1 and glucagon receptors, CagriSema enhances insulin secretion, reduces glucagon secretion when appropriate, slows gastric emptying, and increases energy expenditure. This dual mechanism produces greater metabolic effects than GLP-1 monotherapy alone, resulting in improved blood glucose control and more substantial weight reduction in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management (in development)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disorders
- Headache
Key clinical trials
- Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (PHASE2)
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (PHASE3)
- Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes (PHASE1)
- A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight (PHASE3)
- A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes (PHASE2)
- A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight (PHASE3)
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (PHASE3)
- A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CagriSema CI brief — competitive landscape report
- CagriSema updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI